- Home
- JHS vs ACRS Comparison
JHS vs ACRS Comparison
Compare JHS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- ACRS
- Stock Information
- Founded
- JHS 1973
- ACRS 2012
- Country
- JHS United States
- ACRS United States
- Employees
- JHS N/A
- ACRS N/A
- Industry
- JHS Finance Companies
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- JHS Finance
- ACRS Health Care
- Exchange
- JHS Nasdaq
- ACRS Nasdaq
- Market Cap
- JHS 134.3M
- ACRS 132.0M
- IPO Year
- JHS N/A
- ACRS 2015
- Fundamental
- Price
- JHS $11.39
- ACRS $2.05
- Analyst Decision
- JHS
- ACRS Hold
- Analyst Count
- JHS 0
- ACRS 4
- Target Price
- JHS N/A
- ACRS $1.00
- AVG Volume (30 Days)
- JHS 32.8K
- ACRS 1.3M
- Earning Date
- JHS 01-01-0001
- ACRS 11-06-2024
- Dividend Yield
- JHS 3.96%
- ACRS N/A
- EPS Growth
- JHS N/A
- ACRS N/A
- EPS
- JHS 0.02
- ACRS N/A
- Revenue
- JHS N/A
- ACRS $27,079,000.00
- Revenue This Year
- JHS N/A
- ACRS N/A
- Revenue Next Year
- JHS N/A
- ACRS N/A
- P/E Ratio
- JHS $553.50
- ACRS N/A
- Revenue Growth
- JHS N/A
- ACRS 26.35
- 52 Week Low
- JHS $9.76
- ACRS $0.77
- 52 Week High
- JHS $11.25
- ACRS $2.72
- Technical
- Relative Strength Index (RSI)
- JHS 37.68
- ACRS 55.69
- Support Level
- JHS $11.38
- ACRS $2.09
- Resistance Level
- JHS $11.87
- ACRS $2.72
- Average True Range (ATR)
- JHS 0.13
- ACRS 0.26
- MACD
- JHS -0.01
- ACRS -0.01
- Stochastic Oscillator
- JHS 2.16
- ACRS 40.71
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash & commercial paper.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.